MCE - Delayed Quote EUR

Oryzon Genomics S.A. (ORY.MC)

Compare
1.5200
-0.0040
(-0.26%)
At close: January 10 at 5:35:17 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Cost of Revenue
--
-13,947.9140
-15,234.1600
-9,869.5340
-8,994.7650
Gross Profit
--
13,947.9140
15,234.1600
9,869.5340
8,994.7650
Operating Expense
13,453.1070
18,497.1070
20,724.0700
16,876.0760
13,284.4040
Operating Income
494.8070
-4,549.1930
-5,489.9100
-7,006.5420
-4,289.6390
Net Non Operating Interest Income Expense
-2,303.5710
-1,859.5710
-1,107.6540
-449.8490
-468.9610
Pretax Income
-6,920.0260
-6,104.0260
-6,556.5060
-7,179.8710
-4,778.7300
Tax Provision
--
-2,751.0830
-2,325.1030
-2,492.9010
-1,379.1730
Net Income Common Stockholders
-4,168.9430
-3,352.9430
-4,231.4030
-4,686.9700
-3,399.5570
Diluted NI Available to Com Stockholders
-4,168.9430
-3,352.9430
-4,231.4030
-4,686.9700
-3,399.5570
Basic EPS
-0.07
-0.06
-0.08
-0.09
-0.06
Diluted EPS
-0.07
-0.06
-0.08
-0.09
-0.06
Basic Average Shares
63,594.3100
60,879.3280
56,042.4200
52,761.5540
52,761.5540
Diluted Average Shares
63,594.3100
60,879.3280
56,042.4200
52,761.5540
52,761.5540
Total Operating Income as Reported
494.8070
-4,549.1930
-5,489.9100
-7,010.5650
-4,294.2230
Total Expenses
-494.8070
4,549.1930
5,489.9100
7,006.5420
4,289.6390
Net Income from Continuing & Discontinued Operation
-4,168.9430
-3,352.9430
-4,231.4030
-4,686.9700
-3,399.5570
Normalized Income
-4,373.5480
-3,506.3968
-4,105.4917
-4,684.5266
-3,396.2960
Interest Income
--
33.9680
11.5810
5.7230
0.1270
Interest Expense
--
1,893.5390
1,119.2350
455.5720
469.0880
Net Interest Income
-2,303.5710
-1,859.5710
-1,107.6540
-449.8490
-468.9610
EBIT
833.5130
-4,210.4870
-5,437.2710
-6,724.2990
-4,309.6420
EBITDA
833.5130
-4,057.6030
-5,270.6090
-6,579.9680
-4,164.5910
Reconciled Cost of Revenue
--
-13,947.9140
-15,234.1600
-9,869.5340
-8,994.7650
Reconciled Depreciation
--
152.8840
166.6620
144.3310
145.0510
Net Income from Continuing Operation Net Minority Interest
-4,168.9430
-3,352.9430
-4,231.4030
-4,686.9700
-3,399.5570
Total Unusual Items Excluding Goodwill
204.6050
204.6050
-195.0980
-3.7430
-4.5840
Total Unusual Items
204.6050
204.6050
-195.0980
-3.7430
-4.5840
Normalized EBITDA
628.9080
-4,262.2080
-5,075.5110
-6,576.2250
-4,160.0070
Tax Rate for Calcs
--
0.0003
0.0004
0.0003
0.0003
Tax Effect of Unusual Items
--
51.1513
-69.1867
-1.2996
-1.3230
12/31/2020 - 12/14/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ROVI.MC Laboratorios Farmaceuticos Rovi, S.A.
63.50
+1.44%
 
PHM.MC Pharma Mar, S.A.
77.20
-1.72%
 
ATRY.MC Atrys Health, S.A.
3.4200
+0.59%
 
CLA.F Akari Therapeutics, Plc
1.1700
0.00%
 
J7Z.SG Jazz Pharmaceuticals PLC
117.95
+2.34%
 
5KW.F SkinBioTherapeutics plc
0.1720
+1.18%
 
7IZ.MU Ziccum AB
0.0298
-29.72%
 
HQ1.MU Oruka Therapeutics Inc. R
18.60
0.00%
 
VYT.MC Vytrus Biotech, S.A.
2.1600
0.00%
 
4AJ0.SG Alk-Abello A/S
19.46
+0.46%